Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have a life expectancy of at least 12 weeks~* Patients with advanced HCC (unresectable, and/or metastatic) which has been histologically or cytologically documented~* Patients must have at least one tumor lesion that meets both of the following criteria:~  * can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)~ * has not been previously treated with local therapy~* Patients who have received local therapy except chemoembolization, such as surgery, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. Local therapy must be completed at least 4 weeks prior to the baseline scan~* Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2~Exclusion Criteria:~* Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated \> 3 years prior to entry is permitted~* History of cardiac disease~* Serious myocardial dysfunction~* Active, clinically serious infections~* Known history of Human Immunodeficiency Virus (HIV) infection~* Known Central Nervous System (CNS) tumors including metastatic brain disease~* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib + Doxorubicin (Type: EXPERIMENTAL): Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)
- Placebo + Doxorubicin (Type: ACTIVE_COMPARATOR): Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).